NEWS & MEDIA

Image Alt Text

Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis

This is the second clinical trial approved by the FDA for Neovacs’ lead product candidate
 
Paris and Boston, July 19th, 2017 – 7:30 am CET – Neovacs (Euronext Growth Paris: ALNEV) a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IFNalpha Kinoid in the treatment of dermatomyositis, which allows the Company to initiate in the US its Phase IIa clinical trial already on-going in European countries.

 

Read More

NEOVACS SUCCESSFULLY RAISES €6.0 MILLION IN PRIVATE...

Paris and Boston, July 31, 2017 – 7:30 am CET– Neovacs (Euronext Growth Paris: ALNEV), (the “Company”) a...

Neovacs Announces FDA Acceptance of a New IND to Expand in U.S....

This is the second clinical trial approved by the FDA for Neovacs’ lead product candidate Paris and Boston,...

Neovacs Announces Positive IDSMB Review for Phase IIb Clinical...

Third positive data review by IDSMB follows completion of patient recruitment Paris and Boston, July 11th, 2017...

NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR...

Agreement grants Centurion Pharma exclusive license to market IFNalpha Kinoid in Turkey   Paris and Boston, July...

NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN...

USE OF EQUITY LINE

Paris and Boston, June 1, 2017 – 8:00 AM CET – Neovacs (Alternext Paris: ALNEV) – Neovacs announces that it has...

NEOVACS AND LUPUS EUROPE JOIN VOICES ON WORLD LUPUS DAY

In order to raise awareness about lupus, the progress made in the development of new treatments, and the importance of...

NEOVACS TO PRESENT CLINICAL DEVELOPMENT UPDATE ON IFNα KINOID...

At the 2nd Global Conference on Myositis May 5-8, 2017 – in Potomac, USA Paris and Boston, May 4, 2017 – 8:00 AM...

Neovacs reports FY 2016 financial results

▪ IFNα Kinoid to treat Lupus received “Fast Track” designation from FDA; Phase IIb ongoing ▪ Extended IFNα...

Neovacs to present kinoid technology and its clinical outlooks...

Paris and Boston, March 9, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the...

Neovacs and Biosense Global LLC sign option agreement worth up...

 – Neovacs receives an upfront fee and is eligible for additional milestone payments and double digit sales...

NEOVACS ISSUED NEW BROAD PATENT IN CHINA FOR IFNα KINOID...

Paris, February 9, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapy for the...

Neovacs Announces Independent Data and Safety Monitoring...

...

NEOVACS TO COLLABORATE WITH THE SUNNYBROOK RESEARCH INSTITUTE...

Paris and Boston, January 5th, 2017 – Neovacs (Alternext Paris: ALNEV)     Neovacs (Alternext Paris: ALNEV)...

NEOVACS REPORTS FIRST POSITIVE IMMUNOGENICITY RESULTS FOR...

Paris and Boston, January 25, 2017 – Neovacs (Alternext Paris: ALNEV),       a leader in active...